Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (I...

Full description

Bibliographic Details
Main Authors: Vincenzo Serretta, Francesco Sommatino, Cristina Scalici Gesolfo, Vito Franco, Giuseppe Cicero, Rosalinda Allegro
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Urology Annals
Subjects:
Bacillus Calmette-Guerin
intermediate risk
intravesical chemotherapy
non muscle invasive bladder cancer
recurrence
Online Access:http://www.urologyannals.com/article.asp?issn=0974-7796;year=2015;volume=7;issue=1;spage=21;epage=25;aulast=Serretta

Internet

http://www.urologyannals.com/article.asp?issn=0974-7796;year=2015;volume=7;issue=1;spage=21;epage=25;aulast=Serretta

Similar Items